216 related articles for article (PubMed ID: 31839747)
1. PPAR δ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell.
Li Y; Wang C; Lu J; Huang K; Han Y; Chen J; Yang Y; Liu B
Int J Med Sci; 2019; 16(12):1593-1603. PubMed ID: 31839747
[No Abstract] [Full Text] [Related]
2. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
3. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
4. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
[TBL] [Abstract][Full Text] [Related]
5. Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3β activation in human liver cells.
Cao J; Feng XX; Yao L; Ning B; Yang ZX; Fang DL; Shen W
Dig Dis Sci; 2014 Feb; 59(2):346-57. PubMed ID: 24132507
[TBL] [Abstract][Full Text] [Related]
6. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
[TBL] [Abstract][Full Text] [Related]
7. Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line.
Zhou D; Li BH; Wang J; Ding YN; Dong Y; Chen YW; Fan JG
PLoS One; 2016; 11(10):e0165224. PubMed ID: 27760195
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism.
Lee MY; Choi R; Kim HM; Cho EJ; Kim BH; Choi YS; Naowaboot J; Lee EY; Yang YC; Shin JY; Shin YG; Chung CH
Exp Mol Med; 2012 Oct; 44(10):578-85. PubMed ID: 22824914
[TBL] [Abstract][Full Text] [Related]
9. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
Sui YH; Luo WJ; Xu QY; Hua J
World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease.
Zeng W; Shan W; Gao L; Gao D; Hu Y; Wang G; Zhang N; Li Z; Tian X; Xu W; Peng J; Ma X; Yao J
Sci Rep; 2015 Nov; 5():16013. PubMed ID: 26525891
[TBL] [Abstract][Full Text] [Related]
11. TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells.
Zhang L; Xie Z; Yu H; Du H; Wang X; Cai J; Qiu Y; Chen R; Jiang X; Liu Z; Li Y; Chen T
Ann Transl Med; 2021 Sep; 9(18):1429. PubMed ID: 34733981
[TBL] [Abstract][Full Text] [Related]
12. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD.
Zheng L; Lv GC; Sheng J; Yang YD
J Gastroenterol Hepatol; 2010 Jan; 25(1):156-63. PubMed ID: 19780876
[TBL] [Abstract][Full Text] [Related]
13. Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.
Yang Y; Tong Y; Gong M; Lu Y; Wang C; Zhou M; Yang Q; Mao T; Tong N
Cell Signal; 2014 Feb; 26(2):268-78. PubMed ID: 24269940
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin protects against palmitic acid or lipopolysaccharide-induced hepatocyte apoptosis through inhibition of MAPKs/iNOS and restoration of Akt/eNOS pathways.
Mao Y; Wang J; Yu F; Li Z; Li H; Guo C; Fan X
Biomed Pharmacother; 2016 Dec; 84():305-313. PubMed ID: 27665476
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes.
Ricchi M; Odoardi MR; Carulli L; Anzivino C; Ballestri S; Pinetti A; Fantoni LI; Marra F; Bertolotti M; Banni S; Lonardo A; Carulli N; Loria P
J Gastroenterol Hepatol; 2009 May; 24(5):830-40. PubMed ID: 19207680
[TBL] [Abstract][Full Text] [Related]
17. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
18. Crocetin ameliorates non-alcoholic fatty liver disease by modulating mitochondrial dysfunction in L02 cells and zebrafish model.
Xu Z; Lin S; Tong Z; Chen S; Cao Y; Li Q; Jiang Y; Cai W; Tong Y; Zahra BS; Wang P
J Ethnopharmacol; 2022 Mar; 285():114873. PubMed ID: 34848360
[TBL] [Abstract][Full Text] [Related]
19. Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model.
Li X; Li J; Lu X; Ma H; Shi H; Li H; Xie D; Dong L; Liang C
Int J Mol Med; 2015 Sep; 36(3):767-75. PubMed ID: 26133486
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
